Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia [see comments]
Authors:
Open Access
- 15 May 1992
- journal article
- Published by American Society of Hematology in Blood
- Vol. 79 (10) , 2555-2565
Abstract
Patients with sickle cell anemia were treated with daily doses of hydroxyurea, to assess pharmacokinetics, toxicity, and increase in fetal hemoglobin (Hb) production in response to the drug. Plasma hydroxyurea clearances were not a useful guide to maximum tolerated doses of the drug. The mean daily single oral dose that could be maintained for at least 16 weeks was 21 mg/kg (range, 10 to 35 mg/kg). Among 32 patients, last HbF levels were 1.9% to 26.3% (mean, 14.9%) with increases in HbF over initial values of 1.4% to 20.2% (mean, 11.2%). The most significant predictors of last HbF were last plasma hydroxyurea level, initial white blood count and initial HbF concentration. Last HbF was not related to beta globin haplotype or alpha globin gene number. No serious toxicity was encountered. Clinically significant bone marrow depression was avoided, and chromosome abnormalities after 2 years of treatment were no greater than those observed before treatment. The period of observation has been too short to evaluate the risk of carcinogenesis. Patient's red cells developed striking macrocytosis. Median red cell Hb concentrations did not change. Hb concentrations increased, on average 1.2 g/dL, but serum erythropoietin levels increased. Patients' body weights increased, and some returned to work or school, but no conclusions regarding therapeutic efficacy could be drawn from this uncontrolled open-label study.Keywords
This publication has 13 references indexed in Scilit:
- Treatment of Sickle Cell Anemia with Hydroxyurea and ErythropoietinNew England Journal of Medicine, 1990
- Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivoAmerican Journal of Hematology, 1989
- Levels of Fetal Hemoglobin Necessary for Treatment of Sickle Cell DiseaseNew England Journal of Medicine, 1988
- Development of radioimmunoassays for human erythropoietin using recombinant erythropoietin as tracer and immunogenJournal of Immunological Methods, 1987
- Stimulation of F-Cell Production in Patients with Sickle-Cell Anemia Treated with Cytarabine or HydroxyureaNew England Journal of Medicine, 1985
- Augmentation of Fetal-Hemoglobin Production in Anemic Monkeys by HydroxyureaNew England Journal of Medicine, 1984
- Origin of the beta S-globin gene in blacks: the contribution of recurrent mutation or gene conversion or both.Proceedings of the National Academy of Sciences, 1984
- Treatment of sickle cell anemia with 5-azacytidine results in increased fetal hemoglobin production and is associated with nonrandom hypomethylation of DNA around the gamma-delta-beta-globin gene complex.Proceedings of the National Academy of Sciences, 1983
- 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons.Proceedings of the National Academy of Sciences, 1982
- Estimation of Small Percentages of Fœtal HæmoglobinNature, 1959